J. Haidar

发表

Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project

William Stafford Noble, Nancy R. Zhang, Stephen C. J. Parker, 2007, Nature.

Backbone flexibility of CDR3 and immune recognition of antigens.

Zhiping Weng, Wei Zhu, Brian G. Pierce, 2014, Journal of molecular biology.

Combinations of affinity-enhancing mutations in a T cell receptor reveal highly nonadditive effects within and between complementarity determining regions and chains.

Z. Weng, J. Haidar, B. Pierce, 2010, Biochemistry.

Structure‐based design of a T‐cell receptor leads to nearly 100‐fold improvement in binding affinity for pepMHC

Zhiping Weng, Brian Pierce, Michael C. Li, 2009, Proteins.

A universal combinatorial design of antibody framework to graft distinct CDR sequences: A bioinformatics approach

J. Haidar, Zhen-ping Zhu, Haifan Zhang, 2012, Proteins.

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

J. Haidar, M. Kalos, S. Eastman, 2020, Cancer Immunology Research.

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

J. Haidar, M. Vieth, S. Eastman, 2017, Molecular Cancer Therapeutics.

Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.

J. Haidar, D. Danila, Xun Zhang, 2001, The Journal of clinical endocrinology and metabolism.

Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen

J. Haidar, J. Dukes, M. W. van der Kamp, 2022, Nature Communications.

Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy

J. Haidar, J. M. Sauder, M. Kalos, 2019, Cancer Chemistry.

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

J. Haidar, M. Kalos, Leyi Shen, 2020, Molecular Cancer Therapeutics.

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells.

J. Haidar, D. Danila, Yunli Zhou, 2002, The Journal of clinical endocrinology and metabolism.

Comparison of predicted extinction coefficients of monoclonal antibodies with experimental values as measured by the Edelhoch method.

J. Haidar, Jaafar N. Haidar, J. Goldstein, 2015, International journal of biological macromolecules.

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.